GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
Remote Relief: How Virtual Support Boosts Mood and Confidence for Families Facing Dementia
Dementia is a health crisis sweeping the globe. Experts estimate that roughly 50 million people worldwide are currently living with this condition. That enormous figure is expected to nearly double to 80 million by 2030 and potentially surpass 150 million by 2050. Alarmingly, a new dementia diagnosis happens every three seconds.
A New Era in Alzheimer's Research: Moving Beyond Amyloid
For decades, the public conversation surrounding Alzheimer’s disease focused almost exclusively on a single culprit: sticky protein deposits in the brain known as amyloid-beta plaques. The dominant theory held that if medicine could simply scrub these plaques away, memory loss and cognitive decline could be halted.
Dementia Risk After 90: New Study Shows Why We're Never In the Clear
It is a common and comforting assumption: if you or your loved ones can make it to 90 years old with a sharp mind, you have somehow beaten the odds. We tend to think that after a certain milestone, the risk of cognitive decline plateaus, and we can finally breathe a sigh of relief.
A Legacy of Mistrust: Understanding and Addressing Vaccine Hesitancy Among People of Color
The recent COVID-19 pandemic has laid bare a stark reality: people of color (POC) are disproportionately hesitant to engage with medical and governmental institutions, particularly regarding vaccinations. This hesitancy, often labeled as "vaccine hesitancy," is not simply a matter of ignorance or fear. It is rooted in a deeply ingrained distrust that stems from a long history of systemic racism and medical discrimination.
Combating Alzheimer's: Current Treatments and Promising Pipeline Drugs
Alzheimer's disease is a devastating neurodegenerative disorder that affects millions worldwide. As the global population ages, the prevalence of Alzheimer's and related dementias is expected to rise significantly.
Beyond Clearing Trash: Blocking the IDOL Enzyme Could Revolutionize Alzheimer's Care
Indiana University researchers have discovered that blocking the IDOL enzyme in neurons doesn't just clear toxic Alzheimer's plaques—it also lowers genetic risk (APOE4) and builds cognitive resilience. Read on to learn how this discovery could pave the way for a revolutionary new pill.